Dyadic International INC: directors' dealings · United States · SEC (Form 4)

About Dyadic International INC

Dyadic International, Inc. (NASDAQ: DYAI) is a U.S.-listed biotechnology company traded on the NASDAQ market in the United States, with headquarters in Jupiter, Florida. For investors, the name sits at the intersection of industrial biotechnology, life-science inputs, and precision fermentation rather than traditional pharmaceutical development. The company traces its roots back to the 1980s, when it began developing industrial enzymes, and its technology base accelerated in the 1990s with the discovery of its proprietary fungal host, Thermothelomyces heterothallica. In 2025, the company broadened its branding to “Dyadic Applied BioSolutions,” signaling a shift from a legacy enzyme story toward a wider applied-biotech platform. Dyadic’s business model centers on two microbial expression platforms, C1 and Dapibus™, which are designed to produce recombinant proteins and enzymes at scale with a cost and speed profile the company believes can compete favorably with legacy systems. The platforms are intended to support non-therapeutic, high-value input proteins for life sciences, food and nutrition, and industrial biotechnology. In practical terms, Dyadic is targeting applications such as cell-culture media ingredients, diagnostics, bioprocessing aids, nutritional proteins, and enzyme solutions for industrial and food use. Key product and program areas include recombinant serum albumin, transferrin, DNase I, growth factors, nucleic-acid enzymes, and non-animal ingredients for the food and nutrition sector. From a competitive perspective, Dyadic remains a niche player relative to large enzyme, fermentation, and biosolutions companies. Its differentiation comes from its proprietary IP, its fungal expression platform, and its ability to turn platform validation into commercial agreements. Rather than relying solely on internal product launches, the company is pursuing a partner-led strategy with names such as Proliant, Fermbox Bio, IBT Bioservices, BRIG Bio, and Inzymes. These relationships are important because they can expand market access, reduce commercialization friction, and create multiple revenue streams through licensing, milestone payments, and potential royalties. Geographically, Dyadic is a United States company, but its commercial footprint is increasingly international through manufacturing, licensing, and distribution partners. Recent developments have been especially notable in 2025 and early 2026. The company reported progress in moving from R&D toward commercialization, including the launch of AlbuFree™ DX with Proliant, an OEM distribution agreement with IBT Bioservices, continued collaboration with Fermbox Bio, and advancement of nutrition-focused programs such as animal-free alpha-lactalbumin. It also highlighted ongoing work on Gates Foundation-supported RSV and malaria antibody programs, plus CEPI/FBS-supported H5 avian influenza efforts. Overall, Dyadic remains an early-stage, commercialization-focused biotech with meaningful optionality, but also execution risk typical of small-cap platform companies.